SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Alleged maple syrup scam in Quebec uncovered by Canadian broadcaster - 2The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- 3REWE launches seventh Pick&Go test store in Hanover
- 4Island Travel Guide: Must-Visit Objections for 2024
- 5Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- Bold Colors, Playful Shapes, Handmade Textures: This Mexico City Home Is 100% Joyful!
- Artemis 2 astronauts are now headed to the moon. Why has it taken humanity so long to go back?
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Mom warns of Christmas gift hazard as daughter recovers in hospital
